Summary: Coagulation factor V (FV) is an essential component of the prothrombinase complex, which activates the zymogen prothrombin to thrombin. Acquired FV inhibitor is rare and clinical symptoms are quite variable. The aim of this study was to summarize the spectrum of the bleeding presentation of acquired FV deficiency and characterize the underlying causes of the clinical symptoms. This study was designed as a descriptive retrospective and 30 case reports were included for further analysis. At least 33 cases of acquired FV inhibitor were investigated. Most patients have a presentation of bleeding and most of those are from hematuria and bleeding at surgical sites. Seven cases of asymptomatic acquired FV inhibitor were also detected. A total of 39.4% (19 of 33) of those cases with acquired FV inhibitor have an unknown cause. For those with known etiologies, chemical and drug-induced causes are the most common (30.8%).
Development of autoantibody against coagulation factor V (FV) is a rare clinical condition with hemorrhagic complications of varying severity (1) . Most cases of acquired FV inhibitor occur spontaneously in older patients, but this condition may be associated with a surgical procedure, administration of antibiotics, tuberculosis, or malignant diseases; some of them, however, are idiopathic (2) . The inhibitor disappears within 10 weeks in most patients and the prolonged presence of an idiopathic FV inhibitor is rare (2) .
The inhibitors have physicochemical properties of immunoglobulins and a few have been characterized as polyclonal IgG antibodies or a mixture of IgM and IgG antibodies (3). The actual etiology and pathophysiologic mechanism of their development is unknown (3) . The aim of this study was to summarize the spectrum of bleeding presentation of acquired FV deficiency and to characterize the underlying causes responsible for the clinical symptoms (1).
MATERIALS AND METHODS
This study was designed as a descriptive retrospective study. A review of the articles concerning acquired factor V inhibitor was performed, using the database of published works cited in the Index Medicus and the Science Citation Index. The literature review focused on the years 1978 to 2004. According to the literature review, reports were recruited for further study. The details of clinical presentations of the patients in all included papers were studied. Exclusion criteria were set for any reports with a lack of complete data or details in English.
RESULTS
According to this study, 30 case reports were included for further analysis. At least 33 cases of acquired FV inhibition were investigated. Most patients have a bleeding presentation (Table 1) , which is most commonly caused by hematuria and bleeding at surgical sites. The author also found seven cases of asymptomatic acquired FV inhibitor. A total of 39.4% (19 of 33) of those cases with acquired FV inhibitor have an unknown cause ( Table 2 ). For those with known etiologies, chemical and drug-induced causes are the most common (30.8%).
DISCUSSION
Coagulation FV is an essential component of the prothrombinase complex, which activates the zymogen prothrombin to thrombin (3) . Acquired FV inhibitor is rare and clinical symptoms are quite variable. The combination of a markedly prolonged partial thromboplastin time and quick prothrombin time and failure of normal plasma to correct these tests, in the presence of a normal thrombin and prothrombin and proconvertin time, seems to be pathognomonic for a factor V inhibitor (31) . Bleeding is the leading symptom; however, some cases are asymptomatic. In these asymptomatic cases, additional laboratory investigations revealed the presence of an inhibitor against coagulation FV, which resulted in coagulopathy.
Here, the author found a wide range of bleeding presentations among the patients with acquired FV inhibitors. The most common sites of bleeding are the urinary tract, a surgical wound, and the gastrointestinal tract. Some cases had more than one bleeding presentation. Some lacked overt bleeding but had abnormal coagulation tests. Some uncommon bleeding presentations such as epistaxis, gingival bleeding, and hemospermia were also found. Of interest, some severe or dead bleeding presentations can also be seen. Those cases include bleeding in the central nervous system and hemolytic uremic syndrome, are usually severe, and usually end in death.
Concerning the underlying etiology, several diseases or conditions are mentioned in association with FV inhibitors. In this study, the author found that chemicals and drugs are the leading causes of inhibitor induction. Fibrin glue or other bovine thrombin products are the main underlying agents. However, Knobl and Lechner (31) said that exposure to bovine thrombin usually came with a better prognosis than exposure to other substances. Antibiotics are another leading causative agent and aminoglycoside is the main antibiotic drug mentioned for inhibitor induction. In addition to chemicals and drugs, there are other identified causes. Several cancerous and autoimmune diseases are found to be associated with acquired FV inhibitors. Some viral infections including human immunodeficiency virus (HIV) infection are also detected. Finally, it should be noted that nearly 40% of all cases showed no underlying cause. Further in-depth analysis for the possible pathogenesis of these cases is recommended.
In conclusion, the author found a wide range of bleeding presentations, with hematuria and bleeding at surgical wounds as the predominant causes. Although inhibitors to factor V are not usually associated with major life-threatening hemorrhage, some cases are fatal. The author also found some asymptomatic cases. Considering the underlying etiology, nearly 40% had no identified cause. For cases with a known etiology, drugs and chemicals are the most common causes. 
